Vericel CORP Form 4 insider transactions

Kevin F Mclaughlin, a Director of Vericel Corp, sold 7,000 shares of common stock on August 12, 2026 for $44.53 per share.

Michael Halpin, Chief Operating Officer of Vericel Corp, sold 10,000 shares of common stock on August 3, 2026 for $46.84 per share.

Jonathan Siegal, Principal Accounting Officer of Vericel Corp, sold 4,500 shares of common stock on July 30, 2026 for $48.90 per share.

Jonathan Siegal, an officer at Vericel Corp, reported transactions involving the purchase and sale of company stock, including sales executed under a Rule 10b5-1 trading plan.

Vericel Corp's Chief Financial Officer, Joseph Anthony Mara Jr., has sold 5,000 shares of common stock as part of a pre-arranged trading plan.

Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, reported transactions involving common stock, including acquisitions under an employee stock purchase plan and sales executed via a Rule 10b5-1 trading plan.

Vericel Corporation Director Kevin F. McLaughlin exercised 7,000 stock options and sold the resulting shares under a Rule 10b5-1 plan.

Vericel Corp Director Paul K. Wotton reported transactions involving the purchase of common stock on May 11, 2026.

Vericel Corp's Chief Financial Officer, Joseph Anthony Mara Jr., sold 5,000 shares of common stock for $40.5 per share under a pre-arranged 10b5-1 trading plan.

Vericel Corp's Principal Accounting Officer, Jonathan Siegal, sold common stock totaling 4,855 shares across two transactions in early May 2026, executed under a pre-arranged 10b5-1 trading plan.

Director Kevin McLaughlin acquired 3,200 shares via RSU vesting and received new equity grants in Vericel Corporation.

Director Alan Rubino acquired 3,200 shares via RSU vesting and was granted 8,000 stock options and 3,200 new RSUs.

Vericel Corporation Director Heidi Hagen acquired 3,200 shares via RSU vesting and received new equity grants in a routine Form 4 filing.

Director Paul Wotton exercised restricted stock units and received new equity grants as part of Vericel Corporation's compensation plan.

Vericel Corporation Chief Medical Officer Jonathan Mark Hopper exercised and sold 3,472 shares under a 10b5-1 plan.

Vericel Corp. Director Alan L. Rubino exercised options to acquire 15,000 shares of common stock at $2.76 per share, increasing his direct ownership.

Vericel Corp Director Heidi Hagen exercised stock options and subsequently sold 15,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Vericel Corp's Chief Legal Officer, Sean C. Flynn, sold 21,421 shares of common stock following the exercise of 15,000 stock options.

Vericel Corp's Chief Operating Officer, Michael Halpin, reported the sale of 10,305 shares of common stock at $35.30 per share, executed under a pre-arranged 10b5-1 trading plan.

Vericel Corp's President and CEO, Dominick Colangelo, reported the vesting of Restricted Stock Units, including a deferral into phantom stock and shares withheld for tax obligations.

Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, reported the vesting of Restricted Stock Units and related common stock transactions, including tax withholdings and deferrals.

Vericel Corp's Principal Accounting Officer, Jonathan Siegal, reported the vesting of Restricted Stock Units and subsequent tax-related share disposals.

Vericel Corp's Chief Financial Officer, Joseph Mara, reported the vesting of restricted stock units and subsequent tax-related share disposals on February 24, 2026.

Vericel Corp's Chief Operating Officer, Michael Halpin, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations.

Vericel's Chief Legal Officer, Sean Flynn, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations.

Vericel Corp Director Kevin F. McLaughlin exercised stock options and subsequently sold 7,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Vericel Corp's Chief Operating Officer, Michael Halpin, exercised stock options and simultaneously sold 10,000 shares of common stock for a gain of $23.82 per share, as part of a pre-arranged 10b5-1 trading plan.

Vericel Corp's Chief Human Resources Officer, Karen Mahoney, reported a pre-planned vesting of 2,625 Restricted Stock Units and the subsequent sale of 771 shares to cover tax obligations, scheduled for July 22, 2025.

Vericel's Chief Medical Officer, Jonathan Hopper, sold 1,652 shares of common stock for $39.14 per share, following an option exercise, as part of a pre-arranged 10b5-1 trading plan.

Vericel Corp Director Paul K Wotton sold 5,000 shares of common stock in two transactions totaling approximately $189,500 under a pre-arranged 10b5-1 plan.